Selected article for: "expression profile and western blot"
Author: Pan, Yanchao; Ke, Zhiyi; Ye, Hong; Sun, Lina; Ding, Xiaoyan; Shen, Yun; Zhang, Runze; Yuan, Jing
Title: Saikosaponin C exerts anti-HBV effects by attenuating HNF1α and HNF4α expression to suppress HBV pgRNA synthesis
  • Cord-id: n97kscde
  • Document date: 2019_9_17
    • ID: n97kscde
    Snippet: OBJECTIVE: Saikosaponin c (SSc), a compound purified from the traditional Chinese herb of Radix Bupleuri was previously identified to exhibit anti-HBV replication activity. However, the mechanism through which SSc acts against HBV remains unknown. In this study, we investigated the mechanism of SSc mediated anti-HBV activity. METHODS: HepG2.2.15 cells were cultured at 37 ℃ in the presence of 1–40 μg/mL of SSc or DMSO as a control. The expression profile of HBV markers, cytokines, HNF1α and
    Document: OBJECTIVE: Saikosaponin c (SSc), a compound purified from the traditional Chinese herb of Radix Bupleuri was previously identified to exhibit anti-HBV replication activity. However, the mechanism through which SSc acts against HBV remains unknown. In this study, we investigated the mechanism of SSc mediated anti-HBV activity. METHODS: HepG2.2.15 cells were cultured at 37 ℃ in the presence of 1–40 μg/mL of SSc or DMSO as a control. The expression profile of HBV markers, cytokines, HNF1α and HNF4α were investigated by real-time quantitative PCR, Elisa, Western blot and Dot blotting. Knockdown of HNF1α or HNF4α in HepG2.2.15 cells was mediated by two small siRNAs specifically targeting HNF1α or HNF4α. RESULTS: We found that SSc stimulates IL-6 expression, leading to attenuated HNF1α and HNF4α expression, which further mediates suppression of HBV pgRNA synthesis. Knockdown of HNF1α or HNF4α in HepG2.2.15 cells by RNA interference abrogates SSc’s anti-HBV role. Moreover, SSc is effective to both wild-type and drug-resistant HBV mutants. CONCLUSION: SSc inhibits pgRNA synthesis by targeting HNF1α and HNF4α. These results indicate that SSc acts as a promising compound for modulating pgRNA transcription in the therapeutic strategies against HBV infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00011-019-01284-2) contains supplementary material, which is available to authorized users.

    Search related documents:
    Co phrase search for related documents
    • absence presence and liver cell: 1, 2, 3, 4
    • absence presence and liver cirrhosis: 1, 2, 3, 4, 5
    • absence presence and liver target: 1
    • absence presence and long term antiviral: 1
    • absence presence and long term treatment: 1, 2
    • action novel mode and acute respiratory syndrome: 1, 2, 3
    • acute respiratory syndrome and adjuvant potent: 1, 2
    • acute respiratory syndrome and adjuvant selection: 1
    • acute respiratory syndrome and liver cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver cell expression: 1, 2
    • acute respiratory syndrome and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver gene: 1, 2
    • acute respiratory syndrome and liver gene expression: 1
    • acute respiratory syndrome and liver occur: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and liver target: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long term antiviral: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long term treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adjuvant selection and long term treatment: 1
    • liver cell and long term treatment: 1